Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IMMP - Immutep Limited - ADR


IEX Last Trade
2.63
0.150   5.703%

Share volume: 218,266
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$2.48
0.15
6.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
8.23%
1 Month
22.33%
3 Months
-8.36%
6 Months
15.35%
1 Year
40.64%
2 Year
34.87%
Key data
Stock price
$2.63
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$1.58 - $3.34
52 WEEK CHANGE
$0.37
MARKET CAP 
382.037 M
YIELD 
N/A
SHARES OUTSTANDING 
145.261 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
09/05/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$129,827
AVERAGE 30 VOLUME 
$159,342
Company detail
CEO: Marc Voigt
Region: US
Website: http://www.immutep.com/
Employees: 52
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

immutep is a globally active biotechnology company, listed on the australian stock exchange and on the nasdaq global market in the us. as a leader in personalized bio-therapeutic products for cancer, immutep is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. immutep's main pipeline of products is based on the lag-3 immune control mechanism which plays a vital role in the regulation of the t cell immune response. the most clinically advanced product is a t cell immunostimulatory factor (apc activator), imp321, for cancer chemoimmunotherapy which has completed early phase ii trials. a number of additional lag-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.

Recent news